Search Results - lung+cancer

14 Results

Sort By:

Dual-Action Inhibition Strategy for KRAS and LKB1 Mutant NSCLC

NU 2023-113 INVENTORS Lillian Eichner (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Reuben Shaw (Salk Institute) SHORT DESCRIPTION A dual drug combination to target KRAS and LKB1 mutant non–small cell lung cancer that results in superior efficacy by enhancing T cell recruitment and reducing tumor burden. BACKGROUND Lung...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s): Reuben Shaw

Keywords(s): Cancer/Oncology, Lung cancer, Repurposed Drugs, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Inhibitors of MNK Kinase for Targeted Cancer and CNS Therapeutics.

NU 2015-098 (NU 2015-098, NU 2018-036, NU 2025-036) INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* SHORT DESCRIPTION MNK kinase inhibitors that reduce cancer cell viability and proliferation and penetrates the brain for potential treatment of glioblastoma and CNS disorders. BACKGROUND Leukemia and brain...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, AML - Acute myeloid leukemia, ASD - Autism Spectrum Disorder, Bladder cancer, Brain cancer, Breast cancer, Cancer/Oncology, CNS - Central Nervous System, Colon cancer, Lung cancer, Neurodegenerative disease, Pancreatic cancer, Prostate cancer, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

Use of nucleotide synthesis inhibitors for targeted therapy in MLL3/4 COMPASS mutant cancer

NU 2022-053 INVENTORS Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)* SHORT DESCRIPTION A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...

Published: 4/29/2026 | Updated: 4/29/2026 | Inventor(s):

Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics

Category(s): Life Sciences > Therapeutics

STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment

SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU 2025-212 IP...

Published: 4/29/2026 | Updated: 4/27/2026 | Inventor(s):

Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics

Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools

Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms

SHORT DESCRIPTION Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs). NU Tech IDs: NU 2018-169, NU 2021-005 PRINCIPAL INVESTIGATOR Peng Ji Northwestern University Feinberg School of Medicine, Department of Pathology IP...

Published: 4/16/2026 | Updated: 4/16/2026 | Inventor(s):

Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics

Category(s): Life Sciences > Therapeutics

Anti-CD73 Monoclonal Antibody for Enhanced Cancer Immunotherapy

NU 2020-207 INVENTORS Bin Zhang* Siqi Chen Jie Fan SHORT DESCRIPTION This invention comprises novel anti-CD73 monoclonal antibody compositions that recognize and inhibit mouse and human CD73. BACKGROUND CD73, an ecto-enzyme associated with adenosine metabolism, is an emerging immune checkpoint that promotes tumor progression by suppressing...

Published: 12/11/2025 | Updated: 1/30/2025 | Inventor(s):

Keywords(s): Brain cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Immunotherapy, Lung cancer, Ovarian cancer, Pancreatic cancer, Therapeutics

Category(s): Life Sciences > Therapeutics

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

3-o-sulfo-galactosylceramide Analogs for Targeting Lung Metastases

Summary: The NCI seeks research co-development partners and/or licensees for the sulfatide analog, C24:2 Description of Technology: Lung metastases represent a major clinical challenge in advanced cancer, with poor survival rates and no effective therapies to prevent their development. Researchers at the National Cancer Institute (NCI) have developed...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Lise Pasquet, Jay Berzofsky, Amy Howell, Masaki Terabe, Kaddy Camara

Keywords(s): 3-o-sulfo-galactosylceramide Analogs, Berzofsky, C24:2, Immunotherapy, lung cancer, Metastasis, Natural Killer cells, NKT cells, Sulfatide Analogs, T Cells

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology

A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma

Description of Technology: Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Simone Difilippantonio, Lionel Feigenbaum, Deborah Householder, Philip Martin, Zoe Ohler, Terry Van Dyke

Keywords(s): EGFR, Epidermal Growth Factor Receptor, GEM, Genetically Engineered Mouse, Lung adenocarcinoma, lung cancer, mouse model, Ohler Weaver, respiratory

Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Prognostic Biomarkers for Patients with Early Stage Lung Cancer

Abstract: Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic...

Published: 5/22/2025 | Updated: 8/2/2023 | Inventor(s): Curtis Harris, Aaron Schetter, Ichiro Akagi, Hirokazu Okayama

Keywords(s): Biomarkers, diagnostic, lung cancer, prognostic assay

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics

1 2